Trial Profile

PBTC-053: A Pediatric Brain Tumor Consortium Phase I/ II and Surgical Study of CX-4945 in Patients With Recurrent SHH Medulloblastoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 04 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Silmitasertib (Primary)
Indications Medulloblastoma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

31 Jan 2025 Planned number of patients changed from 60 to 66.
31 Jan 2025 Planned End Date changed from 7 Feb 2029 to 21 Feb 2030.
31 Jan 2025 Planned primary completion date changed from 8 Dec 2028 to 22 Dec 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com